Cybrexa: pH-based tumor targeting

How Cybrexa’s delivery platform could reduce PARP inhibitor toxicity in cancer

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors.

Cybrexa uses its alphalex technology to conjugate a cancer agent to a pH-sensitive peptide via an undisclosed linker. The peptide forms a transmembrane α-helix only

Read the full 597 word article

How to gain access

Continue reading with a
two-week free trial.